Dihydroxyacetone is a process solvent in pharmaceutical manufacturing whose residual presence in drug substances is controlled by ICH Q3C PDE-derived concentration limits. Its physicochemical properties—vapour pressure, water miscibility, and octanol-water partition coefficient—govern both its solvent utility in process chemistry and the efficiency of its removal during drying steps. The PDE for Dihydroxyacetone is calculated by dividing the critical study NOAEL by a composite uncertainty factor comprising F1 for interspecies extrapolation, F2 for intraspecies variability, and F3 for study duration adjustment relative to chronic exposure.
The intraspecies uncertainty factor F2 for Dihydroxyacetone covers the range of pharmacokinetic and pharmacodynamic variability within the human population, ensuring the derived PDE is protective for sensitive subgroups including paediatric patients with immature CYP450 activity, elderly patients with reduced hepatic and renal clearance, patients wit
